Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
Linda T VahdatPeter SchmidAndres Forero-TorresKimberly BlackwellMelinda L TelliMichelle MeliskoVolker MöbusJavier CortesAlberto J MonteroCynthia MaRita NandaGail S WrightYi HeThomas HawthorneRebecca G BagleyAbdel-Baset HalimChristopher D TurnerDenise A YardleyPublished in: NPJ breast cancer (2021)
The METRIC study (NCT#0199733) explored a novel antibody-drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m2 PO daily d1-14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.
Keyphrases
- phase iii
- open label
- phase ii study
- poor prognosis
- metastatic breast cancer
- locally advanced
- clinical trial
- placebo controlled
- double blind
- metastatic colorectal cancer
- end stage renal disease
- chronic kidney disease
- stem cells
- physical activity
- drug delivery
- free survival
- cancer therapy
- ejection fraction
- study protocol
- squamous cell carcinoma
- prognostic factors
- sleep quality